Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S C Gordon

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
Journal of Viral Hepatitis|December 22, 1999
Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled studyM G Mutchnick, K L Lindsay, E R Schiff, et al.
Journal of Viral Hepatitis|February 26, 2018
Impact of sustained virologic response on risk of type 2 diabetes among hepatitis C patients in the United StatesJ Li, T Zhang, S C Gordon, et al.
Alimentary Pharmacology & Therapeutics|May 29, 2013
Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirinS C Gordon, E M Yoshida, E J Lawitz, et al.
Journal of Viral Hepatitis|July 2, 2013
Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirinM P Manns, P J Pockros, G Norkrans, et al.
HLA|July 12, 2017
HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestryE K K Henriksen, M K Viken, M Wittig, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
Journal of Viral Hepatitis|December 22, 1999
Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled studyM G Mutchnick, K L Lindsay, E R Schiff, et al.
Journal of Viral Hepatitis|February 26, 2018
Impact of sustained virologic response on risk of type 2 diabetes among hepatitis C patients in the United StatesJ Li, T Zhang, S C Gordon, et al.
Alimentary Pharmacology & Therapeutics|May 29, 2013
Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirinS C Gordon, E M Yoshida, E J Lawitz, et al.
Journal of Viral Hepatitis|July 2, 2013
Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirinM P Manns, P J Pockros, G Norkrans, et al.
HLA|July 12, 2017
HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestryE K K Henriksen, M K Viken, M Wittig, et al.
Pageof 10